SPRC - Scisparc Ltd
Scisparc Ltd Logo

SPRC - Scisparc Ltd

https://scisparc.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
GlobeNewswire • 1 month, 1 week ago • score: 0.09
TEL AVIV, Israel, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- SciSparc Ltd. ( Nasdaq: SPRC ) ( "Company" or "SciSparc" ) , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that ...
Neutral
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
GlobeNewswire • 1 month, 2 weeks ago • score: 0.14
TEL AVIV, Israel, July 30, 2025 ( GLOBE NEWSWIRE ) -- SciSparc Ltd. ( Nasdaq: SPRC ) ( "Company" or "SciSparc" ) , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

SciSparc Ltd., a specialized clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company is headquartered in Tel Aviv, Israel.

52W High
$24.36
52W Low
$2.00
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.90
Valuation
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
1.21
EV/Revenue (<3 favorable)
1.23
P/S (TTM) (<3 favorable)
2.77
P/B (<3 favorable)
0.44
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.50%
Shares Outstanding
1,622,300
Float
514,580
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
1,306,000
Gross Profit (TTM)
506,000
EPS (TTM)
-22.66
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-7.97%
ROE (TTM) (>15% strong)
-0.81%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.49
Momentum
Bearish momentum
Value
-1.1584
Previous
-1.1825
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025